News

New biomarker for Alzheimer onset
Enlarge image

ResearchBelgiumFinlandUK

New biomarker for Alzheimer onset

27.06.2012 - GE Healthcare and the VTT Technical Research Centre have joint forces on validating a biomarker signature in a large patient cohort.

Espoo/Chalfont St Giles/Beerse – Last December, researchers from the VTT discovered a serum biochemical signature which predicts progression to Alzheimer’s disease (AD) months or even years before the first symptoms of the disease occur (Transl. Psychiatry 1, e57). Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer’s disease may also help in identifying new therapeutic avenues. The first research projects have already begun, said VTT’s research professor Matej Orešič to EuroBiotechNews.eu. "We use a key biomarker metabolite (2,4-dihydroxybutanoic acid) that is a known cerebrospinal fluid (CSF) metabolite. We have preliminary data linking this metabolite measured in CSF to AD", says Orešič.

In 2010 GE Healthcare entered into a “biosignatures initiative” alliance with Janssen Pharmaceutica N.V. to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.

Orešič said: “We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programmes and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has, over the past years, built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE’s and Janssen’s biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options.”

http://www.european-biotechnology-news.com/news/news/2012-02/new-biomarker-for-alzheimer-onset.html

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

M&ASwitzerland

09.06.2015 Monsanto plans to acquire Syngenta AG, but seems reluctant to dig deep into its pockets. The Swiss crop chemical maker has now rejected the second offer from the US company.

InnovationPolandEU

05.06.2015 Polish drug maker Polpharma has received a €45m loan from the European Investment Bank to further its biosimilar research. The operation is part of InnovFin, a new programme set up to support innovative research.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • EVOCUTIS (UK)0.22 GBP15.79%
  • ADOCIA (F)68.80 EUR9.21%
  • WILEX (D)3.90 EUR8.94%

FLOP

  • SANTHERA (CH)89.00 CHF-5.82%
  • OXFORD BIOMEDICA (UK)9.15 GBP-5.67%
  • NEUROVIVE PHARMACEUTICAL AB (S)21.90 SEK-5.19%

TOP

  • PROTHENA PLC (IE)51.28 USD30.0%
  • DBV Technologies (F)52.65 EUR22.4%
  • BIOINVENT INTERNATIONAL AB (S)2.61 SEK17.0%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)21.90 SEK-54.2%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • CELLECTIS (F)31.83 EUR-22.2%

TOP

  • ADOCIA (F)68.80 EUR386.2%
  • WILEX (D)3.90 EUR358.8%
  • 4SC (D)4.39 EUR352.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • ACTIVE BIOTECH (S)9.00 SEK-69.6%
  • NEOVACS (F)1.19 EUR-67.5%

No liability assumed, Date: 29.06.2015